Cutia Therapeutics

Cutia Therapeutics is an investment holding company focused on dermatology treatment and care. It researches, develops, manufactures, and commercializes scalp and skin care products in the People's Republic of China and Hong Kong. Its pipeline includes CU-40102, a topical finasteride spray for androgenetic alopecia, and CU-10201, a topical 4% minocycline foam for acne vulgaris. The company is also developing CU-20401 for submental fat, CU-40101 for androgenetic alopecia, and CU-30101 for topical anesthesia. Incorporated in 2019, it is headquartered in Shanghai, China.